---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-035339"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:14:11.076982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports 29.5-month median OS in low PD-L1 head and neck cancer cohort

## Summary
- Median overall survival (mOS) of 29.5 months in CPS 1-19 cohort from VERSATILE-002 Phase 2 trial.
- Published mOS for Keytruda monotherapy was 10.8 months; for Keytruda plus chemo 12.3 months.
- Approximately 60% of trial patients (n=32) had low PD-L1 expression, a historically difficult-to-treat subset.
- Data suggests PDS0101 + Keytruda may eliminate need for chemotherapy in this population.

## SEC filing metadata
- accession: 0001140361-25-035339
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/0001140361-25-035339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/ef20055698_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-035339
- JSON: https://secwatch.observer/filing/0001140361-25-035339.json
- Plain text: https://secwatch.observer/filing/0001140361-25-035339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.